Mersana Therapeutics, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 88.23. In total, the insiders bought 4 689 637 and sold 264 061 MRSN shares in the last 100 trades.

Insider Power

(Last 100 transactions)
88.23
Buy 4 689 637 Shares
Sell 264 061 Shares

Historical Insider Trades

Date Type Action Person Amount
Jul 01, 2024 Stock Option (right to buy) Buy Alleva Lawrence M 8 972
Jun 11, 2024 Stock Option (right to buy) Buy Hack Andrew A. F. 55 000
Jun 11, 2024 Stock Option (right to buy) Buy Protopapas Anna 55 000
Jun 11, 2024 Stock Option (right to buy) Buy Mott David M 55 000
Jun 11, 2024 Stock Option (right to buy) Buy Hege Kristen 55 000
Jun 11, 2024 Stock Option (right to buy) Buy Diaz Allene M. 55 000
Jun 11, 2024 Stock Option (right to buy) Buy Dere Willard H 55 000
Jun 11, 2024 Stock Option (right to buy) Buy Alleva Lawrence M 55 000
Apr 01, 2024 Stock Option (right to buy) Buy Alleva Lawrence M 3 996
Jan 16, 2024 Common Stock Sell Protopapas Anna 29 399
Jan 16, 2024 Common Stock Sell Misra Tushar 3 357
Jan 16, 2024 Common Stock Sell Mandelia Ashish 5 025
Jan 16, 2024 Common Stock Sell Lowinger Timothy B 10 409
Jan 16, 2024 Common Stock Sell Carvajal Alejandra 4 381
Jan 16, 2024 Common Stock Sell Deschuytner Brian 9 327
Jan 16, 2024 Common Stock Sell Bala Mohan 3 431
Jan 15, 2024 Common Stock Buy Protopapas Anna 17 708
Jan 15, 2024 Common Stock Buy Protopapas Anna 21 250
Jan 15, 2024 Restricted Stock Unit Sell Protopapas Anna 21 250
Jan 15, 2024 Restricted Stock Unit Sell Protopapas Anna 17 708
Jan 15, 2024 Stock Option (Right to Buy) Buy Misra Tushar 187 500
Jan 15, 2024 Restricted Stock Unit Buy Misra Tushar 41 667
Jan 15, 2024 Stock Option (Right to Buy) Buy Mandelia Ashish 75 000
Jan 15, 2024 Common Stock Buy Mandelia Ashish 833
Jan 15, 2024 Common Stock Buy Mandelia Ashish 4 519
Click to get the best stock tips daily for free!

About Mersana Therapeutics, Inc.

Mersana Therapeutics. Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development ... MRSN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT